TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TEVA - US8816242098 - ADR
28.46 USD
+0.05 (+0.18%)
28.46 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to TEVA. TEVA was compared to 191 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of TEVA while its profitability can be described as average. TEVA has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year TEVA was profitable.
In the past year TEVA had a positive cash flow from operations.
TEVA had negative earnings in 4 of the past 5 years.
Each year in the past 5 years TEVA had a positive operating cash flow.
1.2 Ratios
TEVA has a better Return On Assets (-0.39%) than 76.56% of its industry peers.
TEVA has a better Return On Equity (-2.31%) than 77.08% of its industry peers.
With an excellent Return On Invested Capital value of 10.49%, TEVA belongs to the best of the industry, outperforming 90.10% of the companies in the same industry.
TEVA had an Average Return On Invested Capital over the past 3 years of 9.12%. This is below the industry average of 12.85%.
The 3 year average ROIC (9.12%) for TEVA is below the current ROIC(10.49%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROIC | 10.49% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
TEVA has a better Operating Margin (22.59%) than 90.10% of its industry peers.
In the last couple of years the Operating Margin of TEVA has grown nicely.
With a decent Gross Margin value of 50.88%, TEVA is doing good in the industry, outperforming 64.58% of the companies in the same industry.
In the last couple of years the Gross Margin of TEVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TEVA is still creating some value.
The number of shares outstanding for TEVA has been increased compared to 1 year ago.
The number of shares outstanding for TEVA has been increased compared to 5 years ago.
Compared to 1 year ago, TEVA has an improved debt to assets ratio.
2.2 Solvency
TEVA has an Altman-Z score of 0.82. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.82, TEVA is in line with its industry, outperforming 53.13% of the companies in the same industry.
TEVA has a debt to FCF ratio of 19.36. This is a negative value and a sign of low solvency as TEVA would need 19.36 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 19.36, TEVA is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
TEVA has a Debt/Equity ratio of 2.46. This is a high value indicating a heavy dependency on external financing.
TEVA's Debt to Equity ratio of 2.46 is on the low side compared to the rest of the industry. TEVA is outperformed by 79.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Altman-Z | 0.82 |
ROIC/WACC1.34
WACC7.81%
2.3 Liquidity
TEVA has a Current Ratio of 1.06. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.06, TEVA is not doing good in the industry: 82.29% of the companies in the same industry are doing better.
A Quick Ratio of 0.77 indicates that TEVA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.77, TEVA is doing worse than 84.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
TEVA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.96%.
TEVA shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.18% yearly.
The Revenue has been growing slightly by 4.40% in the past year.
The Revenue has been decreasing by -0.41% on average over the past years.
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)4.4%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
3.2 Future
Based on estimates for the next years, TEVA will show a small growth in Earnings Per Share. The EPS will grow by 7.86% on average per year.
The Revenue is expected to grow by 1.72% on average over the next years.
EPS Next Y8.24%
EPS Next 2Y6.07%
EPS Next 3Y7.86%
EPS Next 5YN/A
Revenue Next Year3.41%
Revenue Next 2Y1.94%
Revenue Next 3Y1.72%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TEVA is valuated reasonably with a Price/Earnings ratio of 10.54.
Compared to the rest of the industry, the Price/Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 90.63% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TEVA to the average of the S&P500 Index (26.49), we can say TEVA is valued rather cheaply.
The Price/Forward Earnings ratio is 10.04, which indicates a very decent valuation of TEVA.
Based on the Price/Forward Earnings ratio, TEVA is valued cheaply inside the industry as 85.94% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of TEVA to the average of the S&P500 Index (23.69), we can say TEVA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.54 | ||
| Fwd PE | 10.04 |
4.2 Price Multiples
88.02% of the companies in the same industry are more expensive than TEVA, based on the Enterprise Value to EBITDA ratio.
79.17% of the companies in the same industry are more expensive than TEVA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.68 | ||
| EV/EBITDA | 9.98 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.28
PEG (5Y)N/A
EPS Next 2Y6.07%
EPS Next 3Y7.86%
5. Dividend
5.1 Amount
TEVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
28.46
+0.05 (+0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.54%
Inst Owner Change-9.15%
Ins Owners0.43%
Ins Owner Change-0.73%
Market Cap32.65B
Revenue(TTM)16.54B
Net Income(TTM)-158.00M
Analysts82.86
Price Target0.07 (-99.75%)
Short Float %4.14%
Short Ratio4.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.24%
Min EPS beat(2)4.65%
Max EPS beat(2)5.84%
EPS beat(4)4
Avg EPS beat(4)3.88%
Min EPS beat(4)2.01%
Max EPS beat(4)5.84%
EPS beat(8)6
Avg EPS beat(8)4.79%
EPS beat(12)7
Avg EPS beat(12)-0.36%
EPS beat(16)9
Avg EPS beat(16)-0.6%
Revenue beat(2)0
Avg Revenue beat(2)-4.72%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)-4.68%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)2.63%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)6
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-1.7%
PT rev (1m)17.63%
PT rev (3m)23.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.8%
EPS NY rev (1m)2.61%
EPS NY rev (3m)2.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)0.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.54 | ||
| Fwd PE | 10.04 | ||
| P/S | 1.96 | ||
| P/FCF | 36.68 | ||
| P/OCF | 23.49 | ||
| P/B | 4.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.98 |
EPS(TTM)2.7
EY9.49%
EPS(NY)2.84
Fwd EY9.96%
FCF(TTM)0.78
FCFY2.73%
OCF(TTM)1.21
OCFY4.26%
SpS14.5
BVpS5.95
TBVpS-11.56
PEG (NY)1.28
PEG (5Y)N/A
Graham Number19.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROCE | 13.29% | ||
| ROIC | 10.49% | ||
| ROICexc | 11.36% | ||
| ROICexgc | 49.13% | ||
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% | ||
| FCFM | 5.35% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score6
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Debt/EBITDA | 3.51 | ||
| Cap/Depr | 48.92% | ||
| Cap/Sales | 3.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 29.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 0.82 |
F-Score6
WACC7.81%
ROIC/WACC1.34
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y8.24%
EPS Next 2Y6.07%
EPS Next 3Y7.86%
EPS Next 5YN/A
Revenue 1Y (TTM)4.4%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
Revenue Next Year3.41%
Revenue Next 2Y1.94%
Revenue Next 3Y1.72%
Revenue Next 5YN/A
EBIT growth 1Y1.19%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.41%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-24.19%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-18.04%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status for TEVA stock?
ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 6 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 10.54 and the Price/Book (PB) ratio is 4.78.
What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.